3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Multiple Myeloma
26
Leukemia, Myeloid, Acute
24
Recurrence
12
Sarcoma
7
Lymphoma, Large B-Cell, Diffuse
6
Neoplasm Metastasis
5
Neurofibrosarcoma
4
Neoplasms, Plasma Cell
4
Lymphoma
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell
3
Thymoma
2
Rhabdoid Tumor
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Liposarcoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Congenital Abnormalities
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Breast Neoplasms
2
Wilms Tumor
1
Interventions
Radiotherapy
5
Cisplatin
5
pembrolizumab
4
Cyclophosphamide
4
Thymectomy
3
Sunitinib
3
130-nm albumin-bound paclitaxel
3
selinexor
2
Pemetrexed
2
Methylprednisolone
2
Etoposide
2
Drug Therapy
2
Doxorubicin
2
Chemoradiotherapy
2
Carboplatin
2
zimberelimab
1
vorolanib
1
regorafenib
1
lenvatinib
1
epacadostat
1
envafolimab
1
bosutinib
1
amrubicin
1
Thoracic Surgery, Video-Assisted
1
TP protocol
1
Ramucirumab
1
Radiotherapy, Adjuvant
1
Radiosurgery
1
Radiofrequency Ablation
1
Radiation Dose Hypofractionation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Thymoma
×
selinexor
×
Clear all
NCT03193437
2023-02-16
SELECT
Georgetown University
Phase 2
Terminated
8 enrolled
11 charts
NCT03466827
2018-03-15
TET-SEL
Rigshospitalet, Denmark
Phase 2
Unknown
25 enrolled